DocumentRX-1822
Issued
Read3 min

FDA clinical pharmacology MAPP takes effect with four review areas

FDA’s MAPP 5100.7 took effect on 10 November. The internal guideline covers multidisciplinary NDA and BLA reviews, final OCP sign-off, user fee target dates and team alignment.

TAG P-6437 · 579 words on the filing

New FDA MAPP sheds light on clinical pharmacology reviews - RAPS
New FDA MAPP sheds light on clinical pharmacology reviews - RAPSKost9n4 / pixabay

Summary of findings

  • MAPP 5100.7 took effect on 10 November.
  • The manual identifies four key areas for clinical pharmacology review.
  • Seven named knowledge areas support the expected OCP synthesis.
  • An OCP Division Director or designee serves as the final review signatory.
  • OCP reviewers should adhere to established user fee target dates.

FDA’s clinical pharmacology manual of procedures and policies, MAPP 5100.7, took effect on 10 November.

By Grace Kim

What changed under MAPP 5100.7?

FDA’s Office of Translational Sciences (OTS) and Office of Clinical Pharmacology (OCP) released the manual. It outlines good review practices, or GRPs, for clinical pharmacology reviews of new drug applications (NDAs) and biologics license applications (BLAs). Both offices operate within FDA’s Center for Drug Evaluation and Research (CDER).

The document serves as a new internal guideline. It does not replace any existing documents. It identifies four key areas that should guide the clinical pharmacology review.

The MAPP frames that work as multidisciplinary assessment. The MAPP states: “clinical pharmacology is a multidisciplinary science.” OCP reviewers are expected to synthesize information from all relevant clinical pharmacology knowledge areas to inform regulatory decisions.

The manual names seven areas within that synthesis:

  • Drug disposition.
  • Pharmacology.
  • Biomarkers.
  • Quantitative methods.
  • Drug safety.
  • Pharmacotherapy.
  • Clinical trial methods.

Takeaway: OCP should synthesize the relevant inputs before forming its official review position.

Who gives final OCP sign-off?

The MAPP defines final accountability within the discipline. It states: “an OCP Division Director or their designee serves as the final review signatory and is responsible for ensuring that the official OCP positions on review issues … are clearly stated.”

The rule assigns both final signature and clarity of official positions to that role. The requirement applies to OCP reviews of NDAs and BLAs.

Takeaway: The final OCP position has one designated signatory.

How do deadlines and team communication work?

OCP reviewers should adhere to established user fee target dates during their reviews. Review teams are required to follow the latest OCP internal quality procedures. Regulatory project management staff should arrange formal meetings as necessary. The MAPP also encourages informal meetings and open communication among OCP review team members and reviewers from other disciplines.

FDA writes:

“Because participation in meetings is issue-based, keeping the entire OCP review team informed of key findings is important throughout the review process.”

“Thus, important review findings that might influence approval or labeling decisions should be discussed among the OCP review team to gain alignment prior to engaging with other members of the CDER review team.”

“Relevant outcomes of interactions with other disciplines outside of OCP that may be relevant to the OCP review should be shared with the rest of the OCP review team.”

The sequence is explicit. Findings that may influence approval or labeling first receive alignment within OCP. The team then engages other CDER disciplines. Relevant outcomes from those interactions return to the full OCP team, keeping all members informed as the review proceeds.

The MAPP supports formal meetings arranged as necessary and informal communication across discipline boundaries.

Takeaway: The wider CDER discussion begins after OCP has aligned its position.

What does this mean for filing teams?

For companies preparing NDAs or BLAs, the practical requirements center on timing, procedures and communication. OCP reviews remain tied to established user fee target dates. Review teams must follow the latest internal quality procedures. Formal meetings should be arranged as needed, while informal exchanges remain encouraged.

The document leaves existing FDA policy documents in place. MAPP 5100.7 adds a good-review-practice manual without replacing prior documents. The process now specifies final OCP sign-off, internal quality steps and team communication around issues that may affect approval or labeling.

Takeaway: Sponsors should expect deadlines, quality procedures and internal alignment to operate as one coordinated review process.

via Regulatory Focus (Google News) (Source)

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.

7 articles

Linked filings

  1. P-6323
  2. E-4696
  3. K-1065
  4. C-4460
  5. E-6700

« Previous filingNext filing »